Search
talquetamab
Indications:
- relapsed or refractory multiple myeloma
Dosage:
- 0.4 mg weekly or 0.8 mg every other week
Mechanism of action:
- bispecific monoclonal antibody against CD3 & GPRC5D
- redirects T-cells to mediate killing of GPRC5D-expressing myeloma cells.
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
bispecific antibody; bispecific monoclonal antibody
References
- Bassett M
Talquetamab Offers New Hope in Relapsed/Refractory Multiple Myeloma.
Bispecific antibody achieves "incredible" response rates over 70% in heavily
pretreated patients.
MedPage Today December 11, 2022
https://www.medpagetoday.com/meetingcoverage/ashhematology/102186
- Chari A, Minnema MC, Berdeja JG et al
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
N Engl J Med. 2022. Dec 10.
PMID: 36507686
https://www.nejm.org/doi/full/10.1056/NEJMoa2204591
- Verkleij CPM, Broekmans MEC, van Duin M et al
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific
antibody talquetamab in multiple myeloma.
Blood Adv. 2021 Apr 27;5(8):2196-2215
PMID: 33890981 PMCID: PMC8095149 Free PMC article